Interestingly, the lentivector co-expressing IL-12 and the PD-L1 silencing shRNA was the only one that counteracted MDSC suppressive activities, potentially underlying the observed anti-melanoma therapeutic benefit (170). The gene discussed is CD274; the disease is melanoma.